Key Publications


Linearity and Bias of Proton Density Fat Fraction as a Quantitative Imaging Biomarker: A Multicenter, Multiplatform, Multivendor Phantom Study.
Hu HH, Yokoo T, Bashir MR, Sirlin CB, Hernando D, Malyarenko D, Chenevert TL, Smith MA, Serai SD, Middleton MS, Henderson WC, Hamilton G, Shaffer J, Shu Y, Tkach JA, Trout AT, Obuchowski N, Brittain JH, Jackson EF, Reeder SB; RSNA Quantitative Imaging Biomarkers Alliance PDFF Biomarker Committee.
Radiology. 2021 Mar;298(3):640-651.


A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
Harrison SA, Bashir MR, Lee KJ, Shim-Lopez J, Lee J, Wagner B, Smith ND, Chen HC, Lawitz EJ.
J Hepatol. 2021 Feb 11:S0168-8278(21)00099-4.


Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis.
Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP, Younes Z, Trotter JF, Gunn NT, Moussa SE, Kohli A, Nelson K, Gottwald M, Chang WCG, Yan AZ, DePaoli AM, Ling L, Lieu HD.
Gastroenterology. 2021 Jan;160(1):219-231.e1.


Imaging diamagnetic susceptibility of collagen in hepatic fibrosis using susceptibility tensor imaging.
Wei H, Decker K, Nguyen H, Cao S, Tsai TY, Dianne Guy C, Bashir M, Liu C.
Magn Reson Med. 2020 Apr;83(4):1322-1330.

NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis.
Harrison SA, Rossi SJ, Paredes AH, Trotter JF, Bashir MR, Guy CD, Banerjee R, Jaros MJ, Owers S, Baxter BA, Ling L, DePaoli AM.
Hepatology. 2020 Apr;71(4):1198-1212.


Increased glutaminolysis marks active scarring in nonalcoholic steatohepatitis progression.
Du K, Chitneni SK, Suzuki A, Wang Y, Henao R, Hyun J, Premont RT, Naggie S, Moylan CA, Bashir MR, Abdelmalek MF, Diehl AM.
Cell Mol Gastroenterol Hepatol. 2020;10(1):1-21.


Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomized, placebo-controlled, phase 2 trial.
Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE.
Lancet. 2019 Nov 30;394(10213):2012-2024.

Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.
Bashir MR, Wolfson T, Gamst AC, Fowler KJ, Ohliger M, Shah SN, Alazraki A, Trout AT, Behling C, Allende DS, Loomba R, Sanyal A, Schwimmer J, Lavine JE, Shen W, Tonascia J, Van Natta ML, Mamidipalli A, Hooker J, Kowdley KV, Middleton MS, Sirlin CB. NASH Clinical Research Network (NASH CRN).
J Magn Reson Imaging. 2019 May;49(5):1456-1466.

Accurate fatty acid composition estimation of adipose tissue in the abdomen based on bipolar multi-echo MRI.
Schneider M, Janas G, Lugauer F, Hoppe E, Nickel D, Dale BM, Kiefer B, Maier A, Bashir MR.
Magn Reson Med. 2019 Apr;81(4):2330- 2346.


Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.
Wildman-Tobriner B, Middleton MM, Moylan CA, Rossi S, Flores O, Chang ZA, Abdelmalek MF, Sirlin CB, Bashir MR.
Gastroenterology. 2018 Nov;155(5):1428-1435.e2.

Accuracy of automated liver contouring, fat fraction, and R2* measurement on gradient multiecho magnetic resonance images.
Stocker D, Bashir MR, Kannengiesser SAR, Reiner CS.
J Comput Assist Tomogr. 2018 Sep/Oct;42(5):697-706.


NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Loomba R.
Lancet. 2018 Mar 24;391(10126):1174- 1185.


Proton Density Fat Fraction Committee. Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis.
Yokoo T, Serai SD, Pirasteh A, Bashir MR, Hamilton G, Hernando D, Hu HH, Hetterich H, Kuhn JP, Kukuk GM, Loomba R, Middleton MS, Obuchowski NA, Song JS, Tang A, Wu X, Reeder SB, Sirlin CB; RSNA-QIBA PDFF Biomarker Committee.
Radiology. 2018 Feb;286(2):486- 498.


Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assisted steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis.
Middleton MS, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, Brunt EM, Kleiner DE, Doo E, Van Natta ML, Tonascia JT, Lavine JE, Neuschwander-Tetri BA, Sanyal A, Loomba R, Sirlin CB; NASH Clinical Research Network.
Gastroenterology. 2017 Sep;153(3):753-761.


Effect of a low-rank denoising algorithm on quantitative MRI-based measures of liver fat and iron.
Allen BC, Lugauer F, Nickel MD, Bhatti L, Dafalla RA, Dale BM, Jaffe TA, Bashir MR.
J Comput Assist Tomogr. May/Jun 2017;41(3):412-416.


Multi-site, multi-vendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat- water phantom.
Hernando D, Sharma SD, Aliyari M, Alvis BD, Arora SS, Hamilton G, Pan L, Shaffer JM, Sofue K, Szevernyi NM, Welch EB, Yuan Q, Bashir MR, Kamel IR, Rice MJ, Sirlin CB, Yokoo T, Reeder SB.
Magn Reson Med. 2017 Apr;77(4):1516-1524.


Stability of liver proton density fat fraction and changes in R2* measurements induced by administering gadoxetic acid at 3T MRI.
Sofue K, Zhong X, Nickel MD, Dale BM, Bashir MR.
Abdom Radiol (NY). 2016 Aug;41(8):1555-64.


Differences in liver imaging and reporting data system categorization between MRI and CT.
Corwin MT, Fananapazir G, Jin M, Lamba R, Bashir MR.
AJR Am J Roentgenol. 2016 Feb;206(2):307-12.


Inter-examination repeatability and spatial heterogeneity of liver iron and fat quantification using MRI-based multistep adaptive fitting algorithm.
Sofue K, Mileto A, Dale BM, Zhong X, Bashir MR.
J Magn Reson Imaging, 2015 Nov;42(5):1281-90.


Computer-aided liver volumetry: Performance of a fully-automated, prototype post-processing solution for whole-organ and lobar segmentation based on MDCT imaging.
Fananapazir G, Bashir MR, Marin D, Boll DT.
Abdom Imaging. 2015 Jun;40(5):1203-12.


Quantification of hepatic steatosis with a multistep adaptive fitting MR imaging approach: prospective validation against MR spectroscopy.
Bashir MR, Zhong X, Nickel MD, Fananapazir G, Kannengiesser SAR, Kiefer B, Dale BM.
AJR Am J Roentgenol. 2015 Feb;204(2):297-306.


Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging.
Zhong X, Nickel MD, Kannengisser SA, Dale BM, Keifer B, Bashir MR.
Magn Reson Med. 2014 Nov;72(5):1353-65.


Automated patient- tailored screening of the liver for diffuse steatosis and iron overload using MRI.
Bashir MR, Zhong X, Dale BM, Gupta RT, Boll DT, Merkle EM.
AJR Am J Roentgenol. 2013 Sep;201(3):583-8.


Automated liver sampling using a gradient dual-echo Dixon-based technique.
Bashir MR, Dale BM, Merkle EM, Boll DT.
Magn Reson Med. 2012 May; 67(5):1469- 77.


Hepatic MR imaging for in vivo differentiation of steatosis, iron deposition and combined storage disorder: single-ratio in / opposed phase analysis vs. dual-ratio Dixon discrimination.
Bashir MR, Merkle EM, Smith AD, Boll DT.
Eur J Radiol. 2012 Feb; 81(2):e101-9.